Clinical trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI) · PI: Najla El Jurdi, M.D.
- RECRUITINGN/ANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University · PI: Depei Wu
- RECRUITINGPhase 3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda · PI: Study Director
- RECRUITINGPhase 4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPhase 1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPhase 1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia · PI: Daniel Reed, MD
- RECRUITINGN/ANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPhase 2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute · PI: Curtis A Lachowiez
- RECRUITINGPhase 1NCT06551584Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTStanford University · PI: Lori Muffly
- RECRUITINGPhase 2NCT06599762Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid LeukemiaUniversity of Manitoba
- RECRUITINGPHASE1, PHASE2NCT06923488Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic SyndromesWest Virginia University · PI: Konstantinos Sdrimas, MD
- RECRUITINGPhase 1NCT06763341A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCity of Hope Medical Center · PI: Amanda Blackmon
- RECRUITINGN/ANCT06945042ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid LeukemiaWake Forest University Health Sciences · PI: Thomas Knight, MD
- RECRUITINGPhase 2NCT07238686Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSBeijing 302 Hospital · PI: Bo Cai, MD
- RECRUITINGPhase 2NCT07028086VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid SarcomaRuijin Hospital
- RECRUITINGPhase 2NCT06847867A Study of Momelotinib in Participants With Low-risk Myelodysplastic SyndromeGlaxoSmithKline
- RECRUITINGPhase 2NCT06903702A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center · PI: Roni Tamari, MD
- RECRUITINGPhase 1NCT07006025A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)Treebough Therapies · PI: Mendel Goldfinger, MD
- RECRUITINGPhase 1NCT07321626Romiplostim N01 for Platelet Recovery After Haploidentical HSCTFirst Affiliated Hospital of Zhejiang University
- RECRUITINGEarly Phase 1NCT06980155XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid LeukemiaShanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07008820Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In JapanBristol-Myers Squibb · PI: Bristol Myers Squibb
- RECRUITINGPhase 2NCT07256210Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell TransplantationFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGPhase 1NCT06047886UAB 2419-CD34 Selection Using the Automated CliniMACS ProdigyUniversity of Alabama at Birmingham
- ACTIVE NOT RECRUITINGNCT07073690Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in ChinaBristol-Myers Squibb · PI: Bristol Myers Squibb
- RECRUITINGPhase 1NCT07347171A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological MalignanciesCullgen (Shanghai),Inc · PI: Jianxiang Wang, MS
- RECRUITINGPhase 1NCT06834282CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)CERo Therapeutics Holdings, Inc.
- RECRUITINGPhase 2NCT06304103A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic SyndromeKind Pharmaceuticals LLC · PI: Yusha Zhu, MD, PhD
- RECRUITINGPhase 1NCT06950034A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)Solu Therapeutics, Inc · PI: Chief Medical Officer, MD, MSc, MBA
- RECRUITINGPhase 1NCT03816319TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsNational Cancer Institute (NCI) · PI: Guillaume Richard-Carpentier
- RECRUITINGN/ANCT06773871Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor ConditionsRigshospitalet, Denmark
- RECRUITINGPhase 1NCT06498973Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantCity of Hope Medical Center · PI: Hoda Z Pourhassan, MD
- RECRUITINGPHASE1, PHASE2NCT06746519BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid LeukemiaChen Suning
- RECRUITINGPhase 2NCT06566742A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.M.D. Anderson Cancer Center · PI: Kelly Chien, MD
- RECRUITINGPhase 3NCT06465953Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationInstitut de Recherches Internationales Servier
- ACTIVE NOT RECRUITINGNCT06971185A Study to Evaluate Treatment Patterns and Effectiveness of LuspaterceptBristol-Myers Squibb · PI: Bristol Myers Squibb
- RECRUITINGPhase 1NCT06594445HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLMasonic Cancer Center, University of Minnesota
- RECRUITINGPhase 1NCT06690827Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCNChongqing Precision Biotech Co., Ltd
- RECRUITINGPhase 2NCT06612944Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M StratificationShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT06692894Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic SyndromesUniversity of Vermont
- RECRUITINGPhase 2NCT06317649Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)National Cancer Institute (NCI) · PI: Jessica K Altman
- RECRUITINGPHASE1, PHASE2NCT06284486A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibM.D. Anderson Cancer Center · PI: Ghayas Issa, MD
- RECRUITINGNCT06764511Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic SyndromeIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Stefania Paolini, MD
- RECRUITINGPhase 1NCT06357182Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaOHSU Knight Cancer Institute · PI: Curtis A Lachowiez
- RECRUITINGPhase 1NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaVanderbilt-Ingram Cancer Center · PI: Somedeb Ball, MD
- RECRUITINGN/ANCT06529250Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLInstitute of Hematology & Blood Diseases Hospital, China · PI: Hui Wei, MD
- RECRUITINGNCT06377579OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid LeukemiaFrench Innovative Leukemia Organisation · PI: Pierre PETERLIN, Dr
- RECRUITINGPhase 2NCT06536959VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSBeijing 302 Hospital
- RECRUITINGPhase 4NCT06571825RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CRHe Huang
- RECRUITINGPhase 2NCT06483906Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · PI: Xianmin Song, MD
- RECRUITINGEarly Phase 1NCT06541405Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid LeukemiaBase Therapeutics (Shanghai) Co., Ltd. · PI: wenting Hu
- ACTIVE NOT RECRUITINGPhase 1NCT06359002Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.Byondis B.V.
- RECRUITINGPHASE1, PHASE2NCT06382168DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaDelta-Fly Pharma, Inc.
- RECRUITINGPhase 1NCT06419634Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeBristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPhase 1NCT06465160A Study to Evaluate the MNV-201 in Patients With Low Risk MDSMinovia Therapeutics Ltd.
- RECRUITINGPhase 1NCT06378437A Study of GLB-001 in Patients With Myeloid MalignanciesHangzhou GluBio Pharmaceutical Co., Ltd. · PI: Gang Lu, Ph.D.
- ACTIVE NOT RECRUITINGNCT06058741A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in ItalyAbbVie · PI: ABBVIE INC.
- RECRUITINGPhase 2NCT05483010Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)Washington University School of Medicine · PI: Amber Afzal, M.D., MSCI
- RECRUITINGPhase 2NCT06232655Cladribine Venetoclax in Monocytic AMLUniversity of Colorado, Denver · PI: Christine McMahon, MD
- RECRUITINGPhase 2NCT06196203A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesAkeso
- RECRUITINGPhase 1NCT05947344A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)Zhejiang ACEA Pharmaceutical Co. Ltd.
- RECRUITINGNCT06116318A Study of c-Kit Mutation as MRD in Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPhase 1NCT05995041Universal CAR-T Cells Targeting AMLShenzhen Geno-Immune Medical Institute
- RECRUITINGN/ANCT04859218Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?McMaster University · PI: Donald Arnold
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06091267PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic SyndromesOtsuka Beijing Research Institute
- ACTIVE NOT RECRUITINGPhase 3NCT06045689A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsBristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGNCT05150561Muscle Dysfunction in Patients With Haematological DiseasesRigshospitalet, Denmark
- RECRUITINGN/ANCT06066242Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense ChemotherapyInstitute of Hematology & Blood Diseases Hospital, China · PI: Hui Wei, MD
- RECRUITINGPhase 1NCT05735184A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLKura Oncology, Inc.
- RECRUITINGPhase 3NCT05994690CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML PatientsPrincess Maxima Center for Pediatric Oncology · PI: Gertjan Kaspers, Prof. Dr.
- ACTIVE NOT RECRUITINGPhase 1NCT05823571Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · PI: Ivana Gojo, MD
- RECRUITINGPhase 2NCT05925504The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPhase 2NCT05583552Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyGCP-Service International West GmbH · PI: Uwe Platzbecker, MD
- RECRUITINGNCT05902416Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromePeking University People's Hospital
- RECRUITINGPHASE1, PHASE2NCT05732103A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesChordia Therapeutics, Inc. · PI: Guillermo Garcia-Manero, MD
- RECRUITINGPhase 2NCT05796570A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesFranziska Wachter · PI: Franziska Wachter, MD
- RECRUITINGPhase 2NCT05736965A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaShanghai Tong Ren Hospital
- RECRUITINGPhase 1NCT05558124CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLH. Lee Moffitt Cancer Center and Research Institute · PI: Onyee Chan, MD
- ENROLLING BY INVITATIONPhase 3NCT05674539Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · PI: Linghui Xia, Professor
- RECRUITINGPhase 1NCT05703542BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic SyndromeEric Stephen Winer, MD · PI: Eric S Winter, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05564650Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeThomas Jefferson University · PI: Gina Keiffer, MD
- RECRUITINGNCT05588154Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesNational Cancer Institute (NCI) · PI: Kathy L McGraw, Ph.D.
- RECRUITINGPhase 1NCT04953910Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentTaiho Oncology, Inc.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05469737A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)Bristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05226455Venetoclax in Patients With MDS or AML in Relapse After AHSCTGroupe Francophone des Myelodysplasies · PI: Thomas CLUZEAU, PHD
- ACTIVE NOT RECRUITINGPhase 2NCT05490446A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Agios Pharmaceuticals, Inc. · PI: Medical Medical Affairs
- RECRUITINGPHASE1, PHASE2NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)M.D. Anderson Cancer Center · PI: Ghayas Issa, MD
- RECRUITINGPhase 2NCT05657639CAV Regimen for R/R AMLThe First Affiliated Hospital of Soochow University
- RECRUITINGPhase 2NCT05365035A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsM.D. Anderson Cancer Center · PI: Guillermo Bravo, MD
- RECRUITINGPhase 1NCT05607199A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and PharmacodynamicsAurigene Discovery Technologies Limited · PI: Akhil Kumar, MD
- RECRUITINGPhase 3NCT04628026Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2University of Ulm · PI: Hartmut Doehner, MD
- RECRUITINGNCT05290662Registry of Patients Having Received oNKord®Glycostem Therapeutics BV
- RECRUITINGPhase 1NCT05342584Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSMontefiore Medical Center · PI: Ioannis Mantzaris, MD
- RECRUITINGN/ANCT06328179Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.Huai'an First People's Hospital
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05356169Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGN/ANCT03595787COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeInstitut Paoli-Calmettes · PI: Cécile Bannier Braticevic, MD
- RECRUITINGNCT05326919The Patient Cohort of the National Center for Precision Medicine in LeukemiaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPhase 2NCT05184842Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLMontefiore Medical Center · PI: Mendel Goldfinger, MD
- RECRUITINGPhase 2NCT04905810Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureBrian Jonas · PI: Brian A Jonas
- ACTIVE NOT RECRUITINGPhase 2NCT05197426A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionBristol-Myers Squibb · PI: Bristol-Myers Squibb
- ACTIVE NOT RECRUITINGN/ANCT04822766A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid LeukemiaAssistance Publique - Hôpitaux de Paris · PI: Rémy DULERY, MD